Menu
← Oncology Approval Tracker
FDA DECISION ·
Breyanzi
lisocabtagene maraleucel · Juno Therapeutics (Bristol Myers Squibb)
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory mantle cell lymphoma after at least two systemic treatment lines, including a BTK inhibitor.
LAMPGEN ANALYSIS
Why it matters
This CAR T indication provides another cellular option after exposure to a BTK inhibitor.
What research teams should watch
Track referral timing, treatment history, bridging therapy and whether patients reached infusion after leukapheresis.
PRIMARY RECORDS